Angelo Brunelli Albertoni Laranjeira

About

I am a scientist with experience in basic and translational research. I have a strong background in cellular & molecular biology and a passion for the discovery of novel biomarkers and targeted-treatment strategies. Currently, I am a Staff Scientist at The Washington University in St. Louis working with Myeloproliferative neoplasms (MPNs) which carries a dismal prognosis. The overall objective of my work is to understand the pathogenetic mechanisms responsible for the initiation and development of MPNs, the factors that drive evolution to sAML, as well as the discovery of new therapies using xenograft mice models to improve patient survival. I have deep interest in translational science and clinical relevant questions in hematological malignancies.

Employment

• Incyte (United States) Principal Research Expert
  2023 - Present
• Washington University in St. Louis Staff Scientist
  2019 - 2023

Education

• National Institutes of Health Postdoctoral Fellow
  2016 - 2019
• Centro Infantil Boldrini Postdoctoral Fellow
  2012 - 2015
• Universidade Estadual de Campinas PhD
  2008 - 2012
• Universidade Estadual de Campinas MSc
  2005 - 2007
• Universidade Estadual de Londrina BSc in Biology
  2000 - 2005

Projects & Funding

Projects & funding information is unavailable.

Publications (34)

• DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression
  Nature Cancer 2022 DOI: 10.1038/s43018-022-00486-8
  +Save
• Multiomic Profiling Reveals Metabolic Alterations Mediating Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
  [] 2022 DOI: 10.1101/2022.12.08.519689
  +Save
• Comprehensive Profiling of Clinical JAK2 Inhibitors in Myeloproliferative Neoplasms
  Blood 2022 DOI: 10.1182/blood-2022-164925
  +Save
• Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies
  Blood 2022 DOI: 10.1182/blood-2022-164912
  +Save
• Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
  Blood 2022 DOI: 10.1182/blood-2022-167786
  +Save
• Title of the paper: Panobinostat (LBH589) increase survival in adult xenografic model of Acute Lymphoblastic Leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP
  [] 2022 DOI: 10.21203/rs.3.rs-1594461/v1
  +Save
• Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
  Blood Advances 2022 DOI: 10.1182/bloodadvances.2020002804
  +Save
• TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models
  Journal of Hematology & Oncology 2021 DOI: 10.1186/s13045-021-01091-5
  +Save
• DUSP6 Mediates Resistance to JAK2 Inhibition and Drives Myeloproliferative Neoplasm Disease Progression
  Blood 2021 DOI: 10.1182/blood-2021-147455
  +Save
• Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia
  Blood Advances 2021 DOI: 10.1182/bloodadvances.2020003627
  +Save
• DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression
  [] 2021 DOI: 10.1101/2021.06.27.449656
  +Save
• Abstract LB-107: TET2 DNMT3A mutations and exceptional response to novel epigenetic agent in human malignancies
  Bioinformatics, Convergence Science, and Systems Biology 2020 DOI: 10.1158/1538-7445.am2020-lb-107
  +Save
• Structural Basis of Colchicine-Site targeting Acylhydrazones active against Multidrug-Resistant Acute Lymphoblastic Leukemia
  iScience 2019 DOI: 10.1016/j.isci.2019.10.003
  +Save
• Abstract 3847: Knockout of DNMT1 using CRISPR gene-editing technology confers resistance to DNMT inhibitors in human breast cancer cells
  Experimental and Molecular Therapeutics 2019 DOI: 10.1158/1538-7445.am2019-3847
  +Save
• CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo
  Human Gene Therapy 2019 DOI: 10.1089/hum.2018.218
  +Save
• Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis
  Experimental Hematology & Oncology 2017 DOI: 10.1186/s40164-017-0078-1
  +Save
• Abstract 5081: Disruption of DNA methyltransferase (DNMT) 1 confers resistance to DNMT inhibitors in human colorectal cancer cells
  Experimental and Molecular Therapeutics 2017 DOI: 10.1158/1538-7445.am2017-5081
  +Save
• Mouse lysine catabolism to aminoadipate occurs primarily through the saccharopine pathway; implications for pyridoxine dependent epilepsy (PDE)
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2017 DOI: 10.1016/j.bbadis.2016.09.006
  +Save
• Identification of Genetic Alterations Associated with Mutant IL7Ralpha in T-ALL
  Blood 2016 DOI: 10.1182/blood.v128.22.5272.5272
  +Save
• Simultaneous detection of lysine metabolites by a single LC–MS/MS method: monitoring lysine degradation in mouse plasma
  SpringerPlus 2016 DOI: 10.1186/s40064-016-1809-1
  +Save